A study published on July 15, 2015 demonstrated that BAR502, a novel FXR and GPBAR1 ligand currently in preclinical development by BAR Pharmaceuticals, does not induce itching in rodent models of cholestasis. BAR502 is a novel dual FXR/GPBAR1 ligand being developed to treat pruritus associated with cholestatic diseases.

1. Novel approach to pruritus in
cholestatic diseases
A study published on July 15, 2015 by Prof.
Fiorucci and its group demonstrates that
BAR502, a novel FXR and GPBAR1 ligand, does
not induce itching in rodent models of
cholestasis.
BAR502 is a novel FXR/GPBAR1 ligand currently
in preclinical development by BAR
Pharmaceuticals (Milan, Italy)
Cipriani S, Renga B, D'Amore C, Simonetti M, De Tursi AA, Carino A, Monti MC, Sepe V, Zampella A, Fiorucci S. Impaired
Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling.
PLoS One. 2015 July 15; 10(7):e0129866